Boston, MA -- (SBWIRE) -- 02/04/2014 -- Global Markets Direct's, 'Fragile X Syndrome - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fragile X Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fragile X Syndrome. Fragile X Syndrome - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Fragile X Syndrome.
- A review of the Fragile X Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Fragile X Syndrome pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
View Full Report Details and Table of Contents
Reasons to Get This Report
- Identify and understand important and diverse types of therapeutics under development for Fragile X Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Fragile X Syndrome pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Companies Mentioned in this Report: F. Hoffmann-La Roche Ltd., Novartis AG, Paratek Pharmaceuticals, Inc., Neuren Pharmaceuticals Limited, Cortex Pharmaceuticals, Inc., Seaside Therapeutics, LLC, Snowdon Inc., Marinus Pharmaceuticals, Inc., Nexgenix Pharmaceuticals, LLC, aFraxis Inc., Alcobra Ltd, Sage Therapeutics, Confluence Pharmaceuticals LLC, SMaRT Therapeutics, Inc.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Fragile X Syndrome Global Clinical Trials Review, H2, 2013
- Fragile X Syndrome - Pipeline Review, H1 2013
- Myelodysplastic Syndrome - Pipeline Review, H2 2013
- Metabolic Syndrome - Pipeline Review, H2 2013
- Irritable Bowel Syndrome - Pipeline Review, H2 2013
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2013
- Acute Coronary Syndrome - Pipeline Review, H2 2013
- Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2013
- Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2013
- Tourette Syndrome - Pipeline Review, H2 2013